Pfizer Collaborates with Industry Partners to Innovate and Upgrade Migraine Patient Care Ecosystem

With the rapid development of the Internet and the Internet of Things, the healthcare industry is embracing transformative opportunities for digital innovation, bringing more diverse possibilities for upgrading patient services. During the 6th China International Import Expo, Pfizer not only showcased advancements in migraine treatment with Rimegepant Orally Disintegrating Tablets (Nurtec)...^®ODT) as a representative of a series of revolutionary重磅 innovative drugs. In collaboration with China Resources Pharmaceutical Commercial Group, they have created an integrated channel solution to quickly and broadly benefit patients in China. Together with JD Health, they have built the first online migraine center based on an internet hospital platform, relying on JD Health's pharmaceutical supply chain and healthcare service capabilities. This provides migraine patients with an integrated "medical-pharmaceutical-management" pathway including "online self-diagnosis - doctor’s light consultation - offline visit - drug supply - online long-term service." Concurrently, multi-dimensional cooperation has been launched with physical and digital technology partners at retail terminals, vertically optimizing the patient service system at the endpoint and creating a new ecosystem for integrated online and offline patient management.

Dingzhong Wan, Head of Pfizer China's Commercial Department"It is stated that: 'The 14th Five-Year Plan for National Health clearly proposes a people-centered development concept, emphasizing the comprehensiveness and continuity of health services. In response to national policies and to fulfill Pfizer's mission of 'delivering breakthrough innovations that change patients' lives,' we hope to engage in all-round, multi-dimensional cooperation with partners across various industries. This will drive the integration from drug research and development innovation to patient service model innovation, providing hundreds of millions of migraine patients with more precise, timely, and comprehensive diagnosis, treatment, and integrated management services. We aim to promote the improvement and upgrading of the entire migraine diagnosis and treatment system.'"

As the third most common disease globally and the second leading cause of disability, migraine severely impairs patients' health, quality of life, and productivity, imposing a heavy disease burden on families, workplaces, and society. Data shows that the annual prevalence of migraine is 14.4%, with approximately 1.04 billion people worldwide suffering from this condition. In China, there are about 130 million patients, accounting for 12.5% of the global patient population, meaning one in every ten adults aged 18–65 experiences migraines. According to the *Chinese Diagnosis and Treatment Guidelines for Migraine (2022)*, only 52.9% of migraine patients seek medical attention, and physicians correctly diagnose the condition in only 13.8% of cases. Significant gaps remain in standardized diagnosis and patient access to care.

Chen Ye, Head of Migraine Business at Pfizer China"Migraine is an emerging discipline that demands rapid growth. Pfizer not only has a series of groundbreaking innovative migraine drug pipelines but also possesses abundant industry resources. Pfizer will unite experts, doctors, academic associations, and other forces from all walks of life to carry out multi-level innovative cooperation, jointly promoting the innovation and exploration of the diagnosis and treatment system in this disease area. Together, we will build a new ecosystem for integrated migraine diagnosis, treatment, and management, ensuring that every migraine patient can receive comprehensive disease management services covering 'diagnosis-prevention-treatment.'"

To further improve the diagnosis and treatment of migraines in China and enhance patient compliance, Pfizer and JD Health will jointly build the first online migraine center based on the Internet hospital platform. The center will undertake three key functions: First, leveraging JD Health's pharmaceutical supply chain and healthcare service capabilities, an integrated online and offline service ecosystem will be established to provide migraine patients with a complete "medical-diagnosis-pharmaceutical-management" pathway that connects "online self-diagnosis-doctor’s light consultation-offline visit-pharmaceutical supply-online long-term services," addressing the current low rate of offline visits. Second, actively explore innovative access, innovative payment methods, and commercial insurance models to meet the diverse needs of migraine patients who can consult and receive medication treatment without leaving home. At the same time, utilizing digital advantages to continuously conduct migraine education campaigns, enhancing public awareness and understanding of migraine diseases, thereby improving patients' quality of life and well-being.

Head of JD Health's Pharmaceutical DivisionSaid: "We are very much looking forward to the Rapitab formulation of Rimegepant (Nurtec).^®ODT) This innovative drug represents a breakthrough change for the current state of diagnosis and treatment for migraine patients. JD Health also hopes to leverage our expertise in internet and digital technology to collaborate with Pfizer in building an online migraine center, thereby providing cross-regional, uninterrupted, personalized diagnosis, treatment, and pharmaceutical services to patients. This will help improve the previous challenges of low patient visitation and compliance rates, enhancing patient satisfaction through integrated online and offline convenient services."

Pfizer's Innovative Product in the Migraine Field: Rimegepant Orally Disintegrating Tablets (Nurtec)^®ODT) is the world's first and only new generation small molecule CGRP (calcitonin gene-related peptide) receptor antagonist orally disintegrating tablet that can be used for both acute treatment and prevention of migraine. Relying on the platform advantages of the CIIE, Nurtec ODT (Rimegepant^®ODT) Since its debut last year, it has been率先 implemented in Boao Lecheng and the Greater Bay Area to accumulate clinical diagnostic experience, benefiting hundreds of migraine patients so far.

In addition, Pfizer's booth at this year's CIIE also featured the world's first and only nasal spray CGRP receptor antagonist for the treatment of acute migraine, Zavzpret™ Nasal Spray. This product will help more patients avoid adverse reactions and first-pass metabolism effects caused by gastrointestinal absorption. Zavzpret™ is expected to be available in Boao Lecheng Pilot Zone in early 2024, offering over 100 million Chinese migraine sufferers a new treatment option.

As the pace of innovative drug launches accelerates, Pfizer is committed to enhancing the accessibility of these drugs and providing patients with higher-quality healthcare services. To achieve this, Pfizer has moved forward with optimizing the pathways for accessing innovative drugs, leveraging the CIIE as an opportunity to collaborate with partners in the broader health industry. Together, they are building a patient-centered new ecosystem, expanding patient terminal services, and creating all-channel innovative solutions. Pfizer signed a strategic cooperation agreement with Beijing Pharmaceutical Co., ltd. to jointly explore integrated channel solutions for migraine products. This collaboration ensures product accessibility at multiple stages, including drug importation, nationwide distribution, tendering processes, and terminal access, allowing Pfizer’s innovative products to quickly and broadly benefit patients in China. The partnership aims to create a closed-loop service covering the entire patient journey from diagnosis, treatment, to medication.

Chairman of China Resources Pharmaceutical Commercial Group, Wu JianjunIt was pointed out that Pfizer has been rooted in China for over 30 years, committed to providing high-quality medical products globally and serving as an important strategic partner for Beijing Pharmaceutical Co., Ltd. Pfizer's migraine pipeline brings new possibilities for collaboration between the two parties, offering broader and more effective treatment options for patients. It is believed that under the impetus of this CIIE, partners, industry professionals, and patients will witness breakthroughs in their respective fields and the expansion of application scenarios. Beijing Pharmaceutical Co., Ltd. is willing to deepen its cooperation with Pfizer, centered on patients. Leveraging its unique advantages in international supply chains and nationwide market network strength across China, Beijing Pharmaceutical will actively support the timely availability of Pfizer’s migraine products for Chinese patients, contributing to the realization of the grand goal of "Healthy China 2030."

At the same time, Pfizer, together with Sino Health Technology, Guoda Pharmacy, and Laobaihua Pharmacy retail chain enterprises, launched the "Fight Headaches, Enjoy Life" vision initiative.

General Manager of Guoda Pharmacy, Sui Yang"Guoda Pharmacy always focuses on the changing needs of consumers. As the public's attention to health issues continues to increase, Guoda Pharmacy will rely on its nationwide store network to help improve the accessibility of innovative migraine medications, quickly respond to emergency needs of migraine patients, and combine the model of 'medical + pharmacy + insurance + healthcare + internet + logistics' to help patients achieve better home-based disease management."

Wang Li, President of Laobaixing Pharmacy"We always adhere to the original aspiration of 'Everything for the common people,' bringing the latest health products to the grassroots populace. We aim not only to alleviate pain but also to treat migraines, continuously advancing the Healthy China Initiative."

In China, there are still many research gaps and a lack of patient insights in the field of migraine diagnosis and treatment. To better promote in-depth collaboration and interaction between industry, academia, and research in the migraine field, and to drive cutting-edge advancements in migraine diagnosis and treatment based on consumer insights, the "China Migraine Category Development Blue Paper" jointly developed by Pfizer and Sino Health Technology will be released in the near future.

Li Junguo, Vice President of Zhongkang Technology"It indicates that the large health industry is entering a 'New Era of Personal Health Responsibility,' marking a parallel demand for disease treatment and health maintenance. Sino Health Technology will fully leverage our in-depth accumulation in end-consumer insights, providing industry references through profound perspectives such as the Blue Book Report. This will facilitate patient-centered new drug development and patient service provision across diverse disease areas, including migraines, ultimately enhancing patients' ability and level of self-health management."